Overgrowth, Hemihypertrophy & Tumour Risk
- BECKWITH-WIEDEMANN SYNDROME (BWS) is a rare IMPRINTING/OVERGROWTH disorder (about 1 in 10,000 live births) caused by dysregulation of imprinted genes at chromosome 11p15.5 (IGF2/H19 and CDKN1C); according to PubMed it is characterised by a predilection for embryonal tumour growth (especially WILMS TUMOUR) together with lateralised overgrowth/hemihypertrophy, macroglossia, macrosomia, anterior abdominal wall defects and hyperinsulinism.
- The SYSTEMIC features include MACROSOMIA, MACROGLOSSIA, ABDOMINAL WALL DEFECTS (omphalocele/umbilical hernia), neonatal HYPERINSULINISM with HYPOGLYCAEMIA (important to treat), visceromegaly (nephromegaly, hepatomegaly) and ear creases/pits; diagnosis can be made on clinical criteria where molecular testing is unavailable.
- The principal ORTHOPAEDIC relevance is LATERALISED OVERGROWTH (hemihypertrophy/hemihyperplasia), producing LIMB-LENGTH DISCREPANCY and limb/segment asymmetry - which is the main reason a child with BWS comes to the orthopaedic surgeon.
- The most important association is the predisposition to EMBRYONAL TUMOURS - especially WILMS TUMOUR (nephroblastoma) and HEPATOBLASTOMA - so REGULAR TUMOUR SURVEILLANCE (abdominal ultrasound at intervals through childhood, with serum alpha-fetoprotein for hepatoblastoma) is MANDATORY, and lateralised overgrowth is itself a marker of higher tumour risk.
- Therefore an orthopaedic surgeon assessing a child with lateralised overgrowth/limb-length discrepancy MUST consider BWS (and related overgrowth syndromes) and ensure the child is in an appropriate TUMOUR SURVEILLANCE programme - recognising the overgrowth is not just a limb issue but a marker of cancer risk.
- MANAGEMENT of the orthopaedic problem is that of LIMB-LENGTH DISCREPANCY: monitor the discrepancy and predicted difference at maturity, and treat with EPIPHYSIODESIS of the longer limb (timed to growth) or, less commonly, lengthening - within a multidisciplinary team that also manages the macroglossia (airway/feeding/speech), hypoglycaemia, abdominal wall defect and the essential tumour surveillance.
- “Beckwith-Wiedemann = 11p15 imprinting/OVERGROWTH disorder (~1 in 10,000): macrosomia, macroglossia, abdominal wall defects (omphalocele), neonatal hyperinsulinism/hypoglycaemia.
- “Orthopaedic relevance = LATERALISED OVERGROWTH (hemihypertrophy) -> LIMB-LENGTH DISCREPANCY.
- “CRITICAL: embryonal-tumour predisposition (WILMS tumour, hepatoblastoma) -> MANDATORY surveillance (abdominal ultrasound +/- AFP); lateralised overgrowth is a tumour-risk marker. Manage discrepancy with epiphysiodesis/lengthening + MDT (macroglossia, hypoglycaemia, tumour screening).
Lateralised overgrowth/hemihypertrophy -> limb-length discrepancy. Manage with epiphysiodesis (timed) or lengthening.
Predisposition to embryonal tumours - Wilms tumour, hepatoblastoma. Tumour surveillance (abdominal ultrasound +/- AFP) is mandatory; overgrowth is a risk marker.
Features, Orthopaedic Relevance & Tumour Risk
Beckwith-Wiedemann syndrome is a rare 11p15.5 imprinting/overgrowth disorder (about 1 in 10,000) with macrosomia, macroglossia, abdominal wall defects (omphalocele), neonatal hyperinsulinism/hypoglycaemia and visceromegaly. Its principal orthopaedic relevance is lateralised overgrowth (hemihypertrophy) causing limb-length discrepancy. Critically, it predisposes to embryonal tumours - especially Wilms tumour and hepatoblastoma - so regular tumour surveillance (abdominal ultrasound +/- serum alpha-fetoprotein) is mandatory, and lateralised overgrowth is itself a marker of higher tumour risk. The orthopaedic surgeon assessing a child with lateralised overgrowth/limb-length discrepancy must therefore consider BWS and ensure the child is in a surveillance programme.
- Limb-length discrepancy: monitor the discrepancy and predicted difference at maturity; treat with epiphysiodesis of the longer limb (timed to growth) or, less commonly, lengthening.
- Tumour surveillance (mandatory): ensure the child is in a programme - abdominal ultrasound at intervals through childhood (for Wilms tumour) and serum alpha-fetoprotein (for hepatoblastoma).
- Multidisciplinary: macroglossia (airway/feeding/speech/possible reduction), neonatal hypoglycaemia, abdominal wall defect repair, genetics/counselling.
- Recognise overgrowth as a marker: lateralised overgrowth flags both the discrepancy and the cancer risk.
The crucial point for the orthopaedic surgeon in Beckwith-Wiedemann syndrome (and in lateralised overgrowth generally) is that the overgrowth is not merely a limb-length issue but a marker of an increased risk of embryonal tumours, especially Wilms tumour (nephroblastoma) and hepatoblastoma. A child presenting with hemihypertrophy and limb-length discrepancy must therefore be recognised as potentially having BWS (or a related overgrowth syndrome) and be in an appropriate tumour-surveillance programme - typically regular abdominal ultrasound through childhood to detect Wilms tumour early, with serum alpha-fetoprotein monitoring for hepatoblastoma - because early detection markedly improves outcome. The orthopaedic management of the limb-length discrepancy itself (monitoring and epiphysiodesis or lengthening) is straightforward, but it must be delivered within multidisciplinary care that also addresses macroglossia, neonatal hypoglycaemia from hyperinsulinism, the abdominal wall defect, and - above all - ensures the tumour surveillance is in place. Missing the syndromic diagnosis behind isolated hemihypertrophy is the error to avoid.
Evidence & Key Studies
Beckwith-Wiedemann syndrome with Wilms tumour and lateralised overgrowth
- Beckwith-Wiedemann syndrome is a rare imprinting/overgrowth disorder (prevalence about 1 in 10,000 live births), characterised by a predilection for embryonal tumour growth, especially Wilms tumour, and manifestations such as lateralised overgrowth/hemihypertrophy, macroglossia, macrosomia, anterior abdominal wall defects and hyperinsulinism.
- The reported child presented with abdominal swelling and limb-length discrepancies, with a clinical diagnosis of BWS made on multifocal Wilms tumour, organomegaly and lateralised overgrowth.
- Clinical criteria can diagnose BWS where confirmatory molecular testing is unavailable, changing management of complications such as Wilms tumour.
According to PubMed, BWS as a rare imprinting/overgrowth disorder (about 1 in 10,000) with a predilection for embryonal tumours (especially Wilms tumour), the manifestations of lateralised overgrowth/hemihypertrophy, macroglossia, macrosomia, abdominal wall defects and hyperinsulinism, the association of limb-length discrepancy, and the ability to diagnose on clinical criteria come from the cited Hailu report. The 11p15.5 imprinting genetics, the hepatoblastoma risk and alpha-fetoprotein surveillance, and the orthopaedic management of limb-length discrepancy (epiphysiodesis/lengthening) are standard, well-established teaching. (See also our Limb-Length Discrepancy, Hemihypertrophy / Overgrowth Syndromes and Epiphysiodesis topics.)
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
“A child is referred with hemihypertrophy and a limb-length discrepancy. Why must you think beyond the limb, and how do you manage it?”
Mnemonics & Memory Aids
BWS
Hook:BWS: Big (overgrowth/macroglossia), Wilms tumour surveillance, Skeletal (limb-length discrepancy).
What it is
- Imprinting/overgrowth disorder (11p15.5 - IGF2/H19, CDKN1C); ~1 in 10,000
- Macrosomia, macroglossia, abdominal wall defects (omphalocele)
- Neonatal hyperinsulinism/hypoglycaemia; visceromegaly
Orthopaedic relevance
- Lateralised overgrowth (hemihypertrophy) -> limb-length discrepancy
- Monitor discrepancy / predicted difference at maturity
- Treat with timed epiphysiodesis of the longer limb (or lengthening)
Critical association
- Embryonal-tumour predisposition: Wilms tumour, hepatoblastoma
- Mandatory surveillance: abdominal ultrasound +/- serum alpha-fetoprotein
- Lateralised overgrowth is a tumour-risk marker (not just a limb issue)